LTS Corp is the US-based subsidiary of Lohmann Therapie Systeme whose headquarters are in Andernach, Germany.  LTS’s research and development focuses on two new technologies to complement and expand the potential of alternative drug delivery systems. In addition to the development of LTS Transdermal and LTS Oral Thin Film technologies, the company also develops innovative microneedle and the ‘active LTS Transdermal’ technology.

LTS Microneedles that are long enough to penetrate the outer layer of skin but too short to irritate nerves and blood vessels. They can be used to inject active substances with larger molecules into the skin, an application that is largely pain-free. Microneedles create tiny holes in the outermost layer of skin, which significantly increases the rate at which the active substance is absorbed. 
LTS is currently researching a number of different microneedles made from different materials and with different gauges, designs and sizes for a wide range of applications.

Biotechnology

Life Sciences

Medical Devices

LTS - Lohmann Therapy Systems

David Doles

Rolf Pracht

Sandra Wiedersberg

Paul Pollio

Mary Boehner

Joseph Lepore

Ariel Santos

Michael Santomieri

The Engineering Team at LTS is responsible for the design, development, and optimization of innovative drug delivery systems, particularly focusing on LTS Transdermal and LTS Oral Thin Film technologies. This diverse team of experts collaborates on creating and refining microneedle technologies to enhance the absorption and delivery of active substances, while ensuring compliance with Good Manufacturing Practices (GMP). Their efforts drive advancements in pain-free, effective drug delivery solutions tailored for various therapeutic applications.

Engineering Team

Quality Assurance Team

Finance and Accounting Team

Engineering Team

About

Team members

Other teams at LTS - Lohmann Therapy Systems

Quality Assurance Team

Finance and Accounting Team